PSP Research LLC acquired a new stake in Alumis Inc. (NASDAQ:ALMS – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 43,769 shares of the company’s stock, valued at approximately $427,000.
Several other institutional investors have also modified their holdings of ALMS. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Alumis by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock valued at $46,000 after acquiring an additional 979 shares during the last quarter. Russell Investments Group Ltd. boosted its position in shares of Alumis by 320.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock valued at $26,000 after acquiring an additional 4,894 shares during the last quarter. CWM LLC boosted its position in shares of Alumis by 1,028.7% during the 3rd quarter. CWM LLC now owns 10,384 shares of the company’s stock valued at $41,000 after acquiring an additional 9,464 shares during the last quarter. New York State Common Retirement Fund boosted its position in shares of Alumis by 173.7% during the 2nd quarter. New York State Common Retirement Fund now owns 11,767 shares of the company’s stock valued at $35,000 after acquiring an additional 7,467 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its position in shares of Alumis by 104.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,770 shares of the company’s stock valued at $47,000 after acquiring an additional 6,027 shares during the last quarter.
Alumis News Summary
Here are the key news stories impacting Alumis this week:
- Positive Sentiment: Chardan Capital raised its price target on Alumis to $40 from $38 and kept a Buy rating, signaling strong upside potential for the stock. Chardan price target raise via Benzinga
- Positive Sentiment: HC Wainwright lifted several earnings estimates for Alumis, including Q2 2026, Q3 2026, Q4 2026, FY2026, and FY2027, which suggests modestly improving expectations for the business. HC Wainwright estimate updates
- Neutral Sentiment: HC Wainwright maintained a Neutral rating with a $25 price target, which is less bullish than Chardan’s view and may temper enthusiasm. HC Wainwright coverage
- Neutral Sentiment: Recent research coverage and forecast updates appear to be the main catalyst, rather than any new operational announcement or clinical update from Alumis. Alumis consensus estimates
- Negative Sentiment: Despite the analyst support, Alumis continues to be expected to report losses across 2026 and 2027, so fundamental profitability remains a risk factor for the stock. Alumis earnings estimates
Analyst Upgrades and Downgrades
Read Our Latest Research Report on ALMS
Alumis Trading Up 1.7%
Shares of NASDAQ:ALMS opened at $21.52 on Wednesday. The business has a 50-day moving average price of $24.20 and a 200 day moving average price of $19.31. The company has a market capitalization of $2.74 billion, a price-to-earnings ratio of -10.87 and a beta of -0.31. Alumis Inc. has a 12-month low of $2.76 and a 12-month high of $30.60.
Alumis (NASDAQ:ALMS – Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.01). Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. The firm had revenue of $1.74 million for the quarter, compared to analysts’ expectations of $2.10 million. As a group, equities research analysts predict that Alumis Inc. will post -2.89 earnings per share for the current fiscal year.
Alumis Profile
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Featured Articles
- Five stocks we like better than Alumis
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Want to see what other hedge funds are holding ALMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alumis Inc. (NASDAQ:ALMS – Free Report).
Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.
